About: RSV hospitalisation and healthcare utilisation in moderately prematurely born infants

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: RSV hospitalisation and healthcare utilisation in moderately prematurely born infants Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	RSV hospitalisation and healthcare utilisation in moderately prematurely born infants
Creator	Greenough, Anne Campbell, Morag Peacock, Janet Shefali-Patel, Deena Watson, Fran Alcazar, Mireia
Source	Medline; PMC
abstract	Respiratory syncytial virus (RSV) infection is associated with chronic respiratory morbidity in infants born very prematurely. Our aims were to determine if infants born moderately prematurely (32–35 weeks of gestation) who had had an RSV hospitalisation, compared to those who had not, had greater healthcare utilisation and related cost of care in the first 2 years. Two thousand and sixty-six eligible infants’ records were examined to identify three groups: 20 infants admitted for an RSV lower respiratory tract infection (RSV), 30 admitted for another respiratory problem (other respiratory) and 108 admitted for a non-respiratory problem/never admitted (non-respiratory). Healthcare utilisation was assessed by examining hospital and general practitioner records and cost of care calculated using the National Scheme of Reference costs and the British National Formulary prices. The mean cost of care in the RSV group (£12,505) was greater than the non-respiratory (£1,178) (95% CI for difference £5,015 to £17,639, p = 0.002) and the other respiratory (£3,356) groups (95% CI for difference £2,963 to £15,606, p < 0.001). The adjusted mean differences in the cost of care were £11,186 between the RSV and non-respiratory groups (95% CI £4,763 to £17,609) and £9,076 (95% CI £2,515 to £15,637) between the RSV and the other respiratory groups. Forty-two of 2,066 eligible infants had an RSV hospitalisation (2%); thus, assuming prophylaxis would reduce the hospitalisation rate by 50%, the number needed to treat was 98. In conclusion, RSV hospitalisation in moderately prematurely born infants is associated with increased health-related cost of care. Nevertheless, if RSV prophylaxis is to be cost-effective, a high risk group of moderately prematurely born infants needs to be identified.
has issue date	2012-01-25(xsd:dateTime)
bibo:doi	10.1007/s00431-012-1673-0
bibo:pmid	22302458
has license	no-cc
sha1sum (hex)	9f23cf6c888606a34c44ea1f22e50418c4f0bbc3
schema:url	https://doi.org/10.1007/s00431-012-1673-0
resource representing a document's title	RSV hospitalisation and healthcare utilisation in moderately prematurely born infants
has PubMed Central identifier	PMC7086998
has PubMed identifier	22302458
schema:publication	Eur J Pediatr
resource representing a document's body	covid:9f23cf6c888606a34c44ea1f22e50418c4f0bbc3#body_text
is schema:about of	named entity 'group' named entity 'adjusted' named entity 'problem' named entity 'cost' named entity 'care' named entity 'MODERATELY' named entity 'HEALTHCARE' named entity 'EXAMINED' named entity 'RECORDS' named entity 'MEAN' named entity 'RSV' named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity 'NATIONAL FORMULARY' named entity 'RISK GROUP' named entity 'GROUP' named entity 'WEEKS OF GESTATION' named entity 'INFANTS' named entity 'REFERENCE' named entity 'BORN' named entity 'A34' named entity 'USING' named entity 'HEALTHCARE' named entity 'GROUPS' named entity 'CALCULATED' named entity 'SCHEME' named entity '282' named entity 'ASSOCIATED WITH' named entity 'RATE' named entity 'HOSPITALISATION' named entity 'AIMS' named entity '108' named entity 'GREATER' named entity 'NEEDED' named entity '50%' named entity 'COSTS' named entity 'BRITISH' named entity 'CONCLUSION' named entity 'COST OF CARE' named entity 'HOSPITAL' named entity 'A35' named entity 'PROBLEM' named entity 'TO IDENTIFY' named entity 'LOWER RESPIRATORY TRACT INFECTION' named entity 'REDUCE' named entity 'BORN' named entity 'INFANTS' named entity 'A32' named entity 'RSV' named entity 'FORTY' named entity 'CHRONIC' named entity 'NATIONAL' named entity 'DETERMINE' named entity 'TREAT' named entity 'HOSPITALISATION' named entity 'ADMITTED' named entity 'ADJUSTED' named entity 'COMPARED' named entity 'RESPIRATORY PROBLEM' named entity 'RELATED' named entity 'INFECTION' named entity 'NEEDS' named entity 'RESPIRATORY MORBIDITY' named entity '2C076' named entity 'RESPIRATORY' named entity 'A31' named entity 'SIXTY' named entity 'NUMBER' named entity 'GENERAL PRACTITIONER' named entity 'OUR' named entity 'PRICES' named entity 'DIFFERENCE' named entity 'MODERATELY' named entity 'PROPHYLAXIS' named entity 'A33' named entity 'THOUSAND' named entity 'INCREASED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software